	US 11,697,680 B2
	Anti-GP73 antibodies and immunoconjugates
Frank Stenner-Liewen, Riehen (CH); Norbert Markuly, Basel (CH); and Heike Liewen, Riehen (CH)
Assigned to CUREAB GMBH, Riehen (CH)
Appl. No. 16/461,449
Filed by CUREAB GMBH, Riehen (CH)
PCT Filed Nov. 21, 2017, PCT No. PCT/EP2017/079870 § 371(c)(1), (2) Date May 16, 2019, PCT Pub. No. WO2018/091724, PCT Pub. Date May 24, 2018.
Claims priority of application No. 16199882 (EP), filed on Nov. 21, 2016.
Prior Publication US 2021/0253678 A1, Aug. 19, 2021
Int. Cl. C07K 16/18 (2006.01); A61K 47/68 (2017.01)

CPC C07K 16/18 (2013.01) [A61K 47/6849 (2017.08); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01)]

47 Claims

1. An antibody or antigen-binding fragment thereof, wherein the antibody comprises a variable heavy (VH) chain comprising CDR1 as defined in SEQ ID NO: 4, CDR2 as defined in SEQ ID NO: 5 and CDR3 as defined in SEQ ID NO: 6 and a variable light (VL) chain comprising CDR1 as defined in SEQ ID NO: 7, CDR2 as defined in SEQ ID NO: 8 and CDR3 as defined in SEQ ID NO: 9.